Tempo Wealth LLC Buys New Position in IQVIA Holdings Inc. $IQV

Tempo Wealth LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 3,477 shares of the medical research company’s stock, valued at approximately $784,000.

A number of other institutional investors have also modified their holdings of IQV. Ameliora Wealth Management Ltd. acquired a new position in IQVIA in the 4th quarter valued at $25,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter valued at $27,000. CrossGen Wealth LLC purchased a new position in IQVIA during the fourth quarter worth about $28,000. Finally, Measured Wealth Private Client Group LLC acquired a new stake in IQVIA in the 3rd quarter worth about $30,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Mizuho set a $215.00 price objective on shares of IQVIA in a research note on Monday, February 23rd. Truist Financial decreased their target price on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Finally, Evercore reiterated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Stock Down 1.5%

Shares of NYSE:IQV opened at $168.14 on Friday. The company has a market capitalization of $28.06 billion, a price-to-earnings ratio of 20.84, a price-to-earnings-growth ratio of 1.46 and a beta of 1.21. The company has a 50 day moving average of $173.72 and a two-hundred day moving average of $191.84. IQVIA Holdings Inc. has a 52-week low of $153.01 and a 52-week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the previous year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has approved a stock buyback program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.